In contrast to the efficacy of monotherapy, we found that the venetoclax/idasanutlin combination is synergistic independent of MCL1 or BCL2 expression levels, suggesting a wide applicability in neuroblastoma. This evidence concerns the gene BCL2 and neuroblastoma.